Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.

Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res. 2008 Oct 01; 14(19):6106-15.

View in: PubMed

subject areas

Animals
Antineoplastic Combined Chemotherapy Protocols
Cell Line, Tumor
Drug Synergism
Fusion Proteins, bcr-abl
Histones
HL-60 Cells
Humans
Hydroxamic Acids
Inhibitor of Apoptosis Proteins
K562 Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Acute
Mice
Microtubule-Associated Proteins
Mutation
Neoplasm Proteins
Piperazines

authors with profiles

WARREN C FISKUS
KAPIL BHALLA